Bayer AG BAYRY recently announced that the FDA had accepted its supplemental new drug application (sNDA) seeking approval for ...

Bayer has won U.S. Food and Drug Administration priority review for its application seeking expanded approval of its kidney-disease drug Kerendia in certain people with heart failure.

The US Food and Drug Administration (FDA) accepted and granted Priority Review designation for Bayer’s (BAYN: DE) supplemental new drug application (sNDA) for a new indication for Kerendia (finerenone ...

Regulators are expected to make a decision in the third quarter of 2025 on Kerendia to treat patients with heart failure with ...

The company is working to expand the labels of its key drugs, Nubeqa and Kerendia, which should boost growth. Successful development of additional drugs is imperative for Bayer amid multiple ...

Berlin: Bayer has announced that the Company has received Priority Review designation from the U.S. Food and Drug ...

Healthcare companies rose as traders sought out sectors that are less vulnerable to swings in economic growth and inflation prospects.

Bayer’s fourth-quarter earnings were in line ... Pharmaceuticals grew by 2.4%, with new drugs Nubeqa (prostate cancer) and Kerendia (metabolic disease) posting strong adjusted growth of 73% ...